Zogenix (ZGNX) closed out September’s crammed clinical trial calendar with an impressive win.

The small biotech company, based in Emeryville, Calif., said its lead drug, ZX008, significantly reduced seizure activity compared to a placebo in children with Dravet syndrome, a rare and severe type of epilepsy.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.